ZEB2 and non-small cell lung carcinoma: Wu et al. showed that the PAX6 protein can directly bind to the promoter region of the ZEB2 gene and mediate the downregulation of E-cadherin through the PI3K/AKT signaling pathway, thereby mediating cell migration, stem cell transformation, and cisplatin resistance, and ultimately affecting the survival of NSCLC patients [66].